{"id":"W2593462836","doi":"10.1182/blood.v128.22.619.619","title":"Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Refractory (planetary science); Internal medicine; Oncology; Population; Lymphoma; Phases of clinical research; Clinical trial; Surgery; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002289286,0.001007377,0.001194277,0.0001708601,0.0003118339,0.001008436,0.0006467498,0.0009266695,0.003568252],"category_scores_gemma":[0.001064886,0.0003765654,0.001157615,0.0003445469,0.0004701279,0.0009175324,0.0003640552,0.002531284,0.0009694586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007708836,"about_ca_system_score_gemma":0.0009478154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005093293,"about_ca_topic_score_gemma":0.001313623,"domain_scores_codex":[0.9995826,0.0002037978,0.00002392044,0.0000798276,0.00003896089,0.00007082789],"domain_scores_gemma":[0.9993705,0.0001159686,0.0001581436,0.00006984078,0.00005075552,0.0002348407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.786838,0.02571767,0.02762692,0.001266771,0.003555343,0.0005213721,0.0003549105,0.002155684,0.04680797,0.0003514754,0.009771221,0.09503277],"study_design_scores_gemma":[0.7241507,0.2016978,0.05931872,0.00008662617,0.001782706,0.0008761784,0.0001199027,0.001691002,0.004060868,0.0004051858,0.005767626,0.0000427431],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901938,0.003199556,0.0003897866,0.0005704978,0.00008588941,0.00113039,0.002228598,0.00006356644,0.002137865],"genre_scores_gemma":[0.9900456,0.00143466,0.0009396927,0.0008666957,0.0001322792,0.001099361,0.004085248,0.00002189058,0.001374482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003568252,"threshold_uncertainty_score":0.01210701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01130224728598575,"score_gpt":0.2363130380389587,"score_spread":0.225010790752973,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}